CD163 and thyroid cancer: In thyroid cancer, Angell and colleagues demonstrated that there was a tendency for BRAF mutant tumors to have higher CD163 expression than CD80, but they also reported that this varied significantly between patients, with some having higher CD80 and others CD163 [44].